About AVT
Browse Articles
Customer Services


Rapid diagnostic HCV antibody assays

Bryce D Smith, Amy Jewett, Jan Drobeniuc, Saleem Kamili

Corresponding author name: Bryce D Smith
Corresponding author e-mail: bli1@cdc.gov

Citation: Antiviral Therapy 2012; 17:1409-1413
doi: 10.3851/IMP2470

Date accepted: 08 June 2012
Date published online: 07 December 2012


Approximately 4.1 million Americans have been infected with HCV and 45–85% of chronically infected persons are unaware of their status. Rapid anti-HCV assays can assist and expedite the identification of those unaware of their infection. Performance characteristics of pre-market rapid anti-HCV assays (Chembio, MedMira and OraSure) have been evaluated. Their sensitivity (78.9–99.3%) and specificity (80–100%) varied. Future investigations could include evaluation of rapid anti-HCV tests in persons who are coinfected with HCV and HIV, and development of rapid HCV-antigen tests and nucleic acid tests.


Copyright © Nucleus Global 2017. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.